Paul Shaw

Papers

1

Total Citations

152

H-Index

1

About

Paul Shaw is a leading figure in solid-state chemistry and pharmaceutical materials science, renowned for pioneering high-throughput crystallization methodologies. His most impactful work, the 2002 study "Iterative High-Throughput Polymorphism Studies on Acetaminophen," has garnered 152 citations and introduced the revolutionary CrystalMax platform—a fully integrated system combining design software, robotic dispensing, and microanalytics. This breakthrough enabled the rapid preparation and characterization of three distinct crystal forms of acetaminophen, including the experimentally elusive Form III, fundamentally transforming how polymorphism is investigated in the pharmaceutical industry. Shaw's contributions have dramatically accelerated the discovery of new solid forms, directly impacting drug development, formulation stability, and intellectual property strategies. By demonstrating that thousands of crystallization experiments could be run iteratively and intelligently, he established a new paradigm for solid-form screening. His work remains a cornerstone reference for researchers in crystal engineering and process chemistry, bridging high-throughput automation with fundamental molecular understanding.

Research Focus

Key Achievements

1
H-Index
1
Papers
152
Total Citations
152
Avg Citations/Paper
🏆 Most Cited Paper
Iterative High-Throughput Polymorphism Studies on Acetaminophen and an Experimentally Derived Structure for Form III
152 citations · 2002
📈 Most Prolific Year: 2002 (1 Papers)
🤝 Key Collaborators: 14

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago